Hostname: page-component-7479d7b7d-m9pkr Total loading time: 0 Render date: 2024-07-13T18:59:16.122Z Has data issue: false hasContentIssue false
  • English
  • Français

Wilson's disease and the neuroleptic malignant syndrome

Published online by Cambridge University Press:  13 June 2014

Peter Buckley ,
Eamonn Carmody  and
Michael Hutchinson
Peter Buckley*
Affiliation:
Cluain Mhuire Family Centre, Blackrock, Co. Dublin
Eamonn Carmody
Affiliation:
Beaumont Hospital, Dublin
Michael Hutchinson
Affiliation:
St. Vincent's Hospital, Dublin
*
Cluain Mhuire Family Centre, Newtownpark Avenue, Blackrock, Co.Dublin
Get access Rights & Permissions [Opens in a new window]

Abstract

Wilson's Disease (Hepatolenticular degeneration) is an uncommon disorder of copper metabolism, characterised by excessive copper deposition in the liver, brain and eyes. Psychiatric symptoms were prominent in eight of the twelve patients originally described by Wilson some 88 years ago. Since then a wide range of psychiatric presentations have been documented including behavioural disturbances, affective psychoses, schizophrenia-like psychoses, intellectual deterioration and dementia. Here we describe a patient who presented with a psychiatric disturbance, was treated with neuroleptic medication and subsequently developed Neuroleptic Malignant Syndrome (NMS).

Keywords

Hepatolenticular degenerationNeuroleptic Malignant Syndrome.
Type
Clinical and Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 7 , Issue 2 , September 1990 , pp. 138 - 139
Copyright
Copyright © Cambridge University Press 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Wilson, SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34: 295–509.CrossRefGoogle Scholar
2.Davidson, K and Bagley, G. Schizophrenia-like psychoses associated with organic disorders of the nervous system – a review of the literature. Br. J. Psychiatry 1969; 4: 113–73.Google Scholar
3.Denning, TR. Psychiatric manifestations of Wilson's Disease. Br. J. Psychiatry 1985; 147: 677–82.CrossRefGoogle Scholar
4.Keck, PE. Pope, HG, and McElroy, SL. Frequency and presentation of Neuroleptic Malignant Syndrome: a prospective study. Am. J. Psychiatry 1987; 144: 1344–46.Google ScholarPubMed
5.Rosebush, P and Stewart, T. A prospective analysis of 24 episodes of Neuroleptic Malignant Syndrome. Am. J. Psychiatry 1989; 146: 717–25.Google ScholarPubMed
6.Caroff, SN. The Neuroleptic Malignant Syndrome. J Clin Psychiatry 1980; 41: 79–83.Google ScholarPubMed
7.McCarthy, A, Bourke, S, Fahy, J, Binchy, I and Fitzgerald, MX. Fatal Recurrence of Neuroleptic Malignant Syndrome. Br. J. Psychiatry 1988; 152: 558–9.CrossRefGoogle ScholarPubMed
8.Kontazakis, V, Slefanis, C, Markidism, T and Serpe, V. Neuroleptic Malignant Syndrome in a patient with Wilson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 1001–2.CrossRefGoogle Scholar
9.Levenson, JL. Neuroleptic Malignant Syndrome. Am. J. Psychiatry 1985; 142: 1137–45.Google ScholarPubMed
10.Caroff, S. Rosenberg, H and Gerber, JC. Neuroleptic Malignant Syndrome and Malignant Hyperthermia. Lancet 1983; 1: 244.CrossRefGoogle ScholarPubMed
11.Hermesh, H. Aizengerg, D, Lapidst, M, and Munitz, H. The relationship between malignant hyperthermia and neuroleptic malignant syndrome. Anaesthesiology 1989; 70: 172–3.CrossRefGoogle ScholarPubMed
12.Burke, RD, Fahns, S, Mayeux, R, Weinberg, H, Louis, K and Willner, JH. Neuroleptic Malignant Syndrome caused by dopamine – depleting drugs in a patient with Huntington disease. Neurology 1981; 31: 1022–26.CrossRefGoogle Scholar
13.Lin, MT. Effects of dopaminergic antagonist and agonist on thermoregulation in rabbits. J Psysiol (Lond) 1979; 282: 471–83.Google Scholar
14.Toru, M. Matsuda, D, Makiquichi, K and Sugano, K. Neuroleptic Malignant Syndrome-like-state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1977; 169: 324–7.CrossRefGoogle Scholar
15.Gibb, WRG. Neuroleptic Malignant Syndrome in Striatonigral Degeneration. Br. J. Psychiatry 1988; 153: 254–5.CrossRefGoogle ScholarPubMed